<DOC>
	<DOCNO>NCT00915655</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( body medication ) , safety , tolerability , efficacy ( effectiveness ) darunavir low-dose ritonavir ( DRV/rtv ) administer daily , combination investigator-selected background regimen consist antiretrovirals ( ARVs ) ie , 2 nucleoside/nucleotide reverse transcriptase inhibitor ( NRTIs ) , treatment-naive ( never treat ) HIV-1 infected adolescent age 12 &lt; 18 year weigh least 40 kg .</brief_summary>
	<brief_title>A Study Evaluate Antiviral Activity Darunavir + Ritonavir HIV-1 Infected Adolescents</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-arm , Phase II study evaluate pharmacokinetics , safety , tolerability , efficacy darunavir/ritonavir ( DRV/rtv ) administer daily , combination investigator-selected background regimen ( 2 NRTIs ) , treatment-naive HIV-1 infect adolescent 48 week . A total 12 patient enrol study . Patients consider treatment-naive never receive treatment ARV medication , include investigational well commercially available ARVs indicate treatment HIV-infection ARVs treatment hepatitis B infection anti-HIV activity . The investigator-selected background regimen consist 2 NRTIs , either zidovudine/lamivudine abacavir/lamivudine , whichever approve market consider local standard care adolescent age 12 &lt; 18 year particular country . The study consist 4-week screening period , 48-week treatment period , 4-week follow-up period . Safety , efficacy , resistance ( reduction effectiveness medication ) , pharmacokinetic analysis , pharmacodynamic ( medication body ) analyse perform Week 24 ( primary analysis ) Week 48 ( final analysis ) . Patients complete 48 week treatment DRV/rtv continue benefit treatment , opportunity continue treatment long benefit medication , DRV commercially available access another source ( eg , access program , government program ) development program discontinue .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Patients document HIV1 infection Body weight least 40 kg screen Screening plasma HIV1 RNA &gt; = 1000 copies/mL Parents legal representative trial patient ( appropriate , depend age local regulation ) willing able give consent assent General medical condition , investigator 's opinion , interfere assessment completion trial Able swallow darunavir tablet ( 400 mg ) ritonavir capsule ( 100 mg ) Patients presence currently active condition include list World Health Organisation ( WHO ) Clinical Stage 4 Any condition ( include , limited , alcohol drug use ) , , opinion investigator , could compromise patient 's safety adherence trial protocol Previous current use antiretrovirals ( ARVs ) Primary acute HIV infection Use investigational agent within 30 day prior screen Use disallow concomitant therapy Pregnant breastfeed Female patient childbearing potential without use effective nonhormonal birth control method willing continue practice birth control method least 30 day end treatment period Patients clinical laboratory evidence significantly decrease hepatic function decompensation ( ie , liver insufficiency ) , irrespective liver enzyme level Any active clinically significant disease ( eg , cardiac dysfunction , pancreatitis , acute viral infection ) finding screen medical history physical examination expect compromise patient 's safety outcome trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>TMC114-TiDP29-C230</keyword>
	<keyword>TMC114-C230</keyword>
	<keyword>TMC114</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>NRTI</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>